Nanoparticles crossing blood-brain barrier need specific design for normal, neurodegenerative or cancerous brain conditions

Julia Y Ljubimova; Eggehard Holler; Keith L Black; Alexander V Ljubimov

doi:10.1080/17435889.2024.2380241

Nanoparticles crossing blood-brain barrier need specific design for normal, neurodegenerative or cancerous brain conditions

Nanomedicine (Lond). 2024;19(23):1863-1866. doi: 10.1080/17435889.2024.2380241. Epub 2024 Aug 7.

Authors

Julia Y Ljubimova¹, Eggehard Holler^{1

2}, Keith L Black^{3

4}, Alexander V Ljubimov^{3

4

5

6}

Affiliations

¹ Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
² Institut für Biophysik und Physikalische Biochemie Universtität, Regensburg, D-93040, Regensburg, Germany.
³ Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
⁴ Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
⁵ Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA.
⁶ Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

PMID: 39109486
PMCID: PMC11457639 (available on 2025-08-07)
DOI: 10.1080/17435889.2024.2380241

No abstract available

Keywords: Alzheimer's and tumor; BBB; CNS immunity; Diabetic retinopathy; blood brain barrier (BBB); cell-specific drug delivery; central nervous system; multifunctional nanoparticles; normal; peptides.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Animals
Blood-Brain Barrier* / metabolism
Brain / metabolism
Brain Neoplasms* / metabolism
Brain Neoplasms* / pathology
Humans
Nanoparticles* / chemistry
Neurodegenerative Diseases / metabolism

Publication types

MeSH terms

Grants and funding